Article and Video CATEGORIES
In partnership with Clinical Care Options, GRACE Founder and President H. Jack West, MD provides this informational video regarding immunotherapy for advanced NSCLC and discussing goals and treatments with your health care providers. We invite you to watch and join the conversation.
For those dealing with questions regarding immune checkpoint inhibitor therapy, we have developed another helpful downloadable pdf for patients, Understanding the Current Landscape of Immune Checkpoint Inhibitor Therapy in Advanced NSCLC: A Resource for Patients.
Also in partnership with Clinical Care Options, we have developed a helpful interactive online tool to help you understand more about your disease and treatment options.
Did you recently receive a diagnosis of non small cell lung cancer?
GRACE has partnered with Clinical Care Options to develop an interactive online tool to help you understand more about your disease and treatment options. The goal of this tool is to help you better understand your diagnosis of locally advanced or metastatic NSCLC, to better understand your treatment options, and to become partners with the oncology team instead of being a bystander in your cancer care. A series of questions developed by the experts allow you to select information about yourself and your cancer that are necessary to consider when making treatment choices in advanced NSCLC.
Answer a series of multiple-choice questions and then get treatment options chosen by the 5 lung cancer experts listed below.
- David R. Gandara, MD, UC Davis Health
- Melissa L. Johnson, MD, Sarah Cannon
- Suresh S. Ramalingam, MD, Emory Winship Cancer Institute
- Heather Wakelee, MD, Stanford University
- H. Jack West, MD, City of Hope
To assist you in gathering information click here to download a PDF consultation checklist with useful questions for your oncologist about your advanced NSCLC disease. For additional tips please see "How to Talk to Your Oncologist". If you are a health care provider, you can find CCO's clinician-focused tool here: https://www.clinicaloptions.com/oncology/programs/nsclc-clinical-insights/interactive-decision-support-tool/nsclc_tool_2018/page-1?origin=2.
Please join the conversation! We would love to hear from you!
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…